MIAMI, Jan. 10, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc., ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (Nasdaq:NRXP), today announced it conducted an investor workshop to support planned expansion of HOPE's network of interventional psychiatry practices focused on the treatment of suicidal depression and PTSD, at the Mar-A-Lago Club in Palm Beach, FL. The event was attended by Qualified ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 6:NRx Pharmaceuticals, Inc. (NRXP) : This bio-pharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 46.2% over the last 60 days.NRx Pharmaceuticals' shares gained 79.3% over the last three months compared with the S&P 500’s advanced of 4.2%. The company possesses a Momentum Score of A.Pro-Dex, Inc. (PDEX) : This medical devi ...

Anticipated capital from funds managed by Smith & Sauer to augment potential bank-financing for acquisition of HOPE Therapeutics clinics and support NRx Pharmaceutical operations. Purchase of $25 million in Series A Preferred Stock in HOPE Therapeutics (non-dilutive to NRXP shareholders) convertible into 1/3 of fully diluted HOPE Therapeutics equity, with a 15% current preferred dividend (non-callable for 2 years) for planned HOPE clinic acquisitions. Purchase $2 million in NRx equity, above the most recen ...

Dura Medical, with initial clinics in Naples and Fort Myers, to anchor the HOPE network in Florida Delivers a full range of precision psychiatry services, including Ketamine and Transcranial Magnetic Stimulation (TMS), to veteran and civilian residents of Florida Stephen Durand, founder of Dura, to serve as Director of Clinic Growth for HOPE in Florida Acquisition expected to be immediately accretive to revenue and EBITDA for NRx MIAMI, Jan. 6, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "C ...

MIAMI, Jan. 3, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., an NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) subsidiary, is inviting Qualified Institutional Investors to an investor workshop to support planned acquisitions for a national network of interventional psychiatry practices focused on treatment suicidal depression and PTSD. The Company has previously announced non-binding Letters of Intent and banking intent for initial clinic acquisitions and has disclosed its intent to acquire and integrate clinics ...

Aiming to be the first FDA-approved medication to treat suicidal depression Designed to help address the needs of the more than 13 million Americans who seriously consider suicide each year (CDC) Completion of NDA filing expected in the first quarter of 2025 Company to participate in 1x1 meetings in San Francisco during the Annual J.P. Morgan Healthcare Conference on January 13-16, 2025, in San Francisco, CA.  To schedule meetings, please contact [email protected] WILMINGTON, Del., Dec. 30, 2024 /PRNewswir ...

NRx Pharmaceuticals, Inc. (NRXP) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a c ...

 WILMINGTON, Del., Nov. 26, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman, CEO and Chief Scientist will present at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.- on Tuesday December 3, 2024 at 1:00PM Eastern Standard Time. HOPE Therapeu ...

NRx-developed training and monitoring methodology in recently completed phase 2b/3 clinical trial of NRX-101 documents higher interrater reliability (IRR) on primary endpoint (MADRS depression scale) than previously reported industry standards Positive implications for conduct of future registration trials for NRX-101 and similar medications. Published in the peer reviewed American Journal of Clinical Psychopharmacology WILMINGTON, Del., Nov. 25, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP ...

财务数据和关键指标变化 - 2024年第三季度运营净亏损较2023年第三季度减少近75%，从610万美元降至160万美元[45] - 2024年第三季度研发费用从2023年的330万美元降至60万美元[45] - 2024年第三季度一般和管理费用从2023年的250万美元微降至240万美元[45] - 2024年前九个月净亏损降至1610万美元，较上一年的2580万美元有所减少，净亏损每股改善1.89美元或54%[46] - 2024年前九个月研发费用为520万美元，较2023年同期的1080万美元减少52%[47] - 2024年前九个月G&A费用从2023年的1230万美元降至1090万美元，减少11%[47] - 截至2024年9月30日，公司有160万美元现金及现金等价物，之后通过安森基金的第二笔540万美元的有担保债务融资增加了现金[48] 各条业务线数据和关键指标变化 - NRX - 100（静脉注射氯胺酮）和NRX - 101（口服治疗双相抑郁症药物）正在推进新药申请，预计2025年实现盈利，包括来自Hope Therapeutics的收入和EBITDA以及药品的预计销售[15] - Hope Therapeutics计划在年底前成为提供挽救生命护理业务并产生首笔收入，已签署两份意向书收购目前有营收且EBITDA为正的介入精神病学集团，收到非稀释性收购融资的初步承诺并处于承销最后阶段[8][9] - Hope Therapeutics目标是到今年年底组建一个营收2500万美元的组织，到明年年底组建一个营收超1亿美元的组织，其瞄准的一流诊所利润率约为30%且有显著增长机会[36][42] 各个市场数据和关键指标变化 - 目前鼻内氯胺酮市场每年约为10亿美元[19] 公司战略和发展方向和行业竞争 - 公司致力于构建综合护理模式，除药物开发外，通过Hope Therapeutics提供包括氯胺酮、经颅磁刺激等多种疗法，以实现更高的患者缓解率（80% - 90%而非50%），目标是建立全国性的精准精神病学诊所网络[38] - 公司是唯一一家致力于开发预防和治疗自杀综合护理路径的公司，在市场上具有独特地位[9] - 公司计划为NRX - 100寻求扩大快速通道指定并获得优先审查，用于所有形式的抑郁症治疗；为NRX - 101提交加速批准的新药申请，用于有自杀倾向或静坐不能的双相抑郁症[20][34] 管理层对经营环境和未来前景的评论 - 自杀是全国性的流行病，公司的首要目标是确保所有需要氯胺酮和其他疗法的精准精神病护理的患者能够获得治疗，目前氯胺酮的非标签使用通常只有自费患者才能获得，NRX - 101一旦批准有望广泛报销[17][28] - 公司预计2025年实现盈利，随着Hope Therapeutics的发展以及两种潜在药物的批准，公司将成为营收和EBITDA为正的生物技术公司和护理服务公司[15][16] 其他重要信息 - 任命Michael Abrams为新的首席财务官，他拥有近三十年的经验[11] - Rich Narido作为临时CFO表现出色，将继续支持Hope Therapeutics的收购；David Feifel作为关键顾问加入，他是国际知名的精准精神病学专家[13][14] - 公司最近完成了第二笔机构投资者的融资，总额达1080万美元，用于偿还之前较昂贵的债务并解决诉讼[15][16] 问答环节所有的提问和回答 问题：关于加速批准的流程，若获得加速批准对PDUFA数据和时间线有何意义，NRX - 100和NRX - 101的PDUFA日期和时间线可能是怎样的[57] - 回答：加速批准是一种流程，对于NRX - 101，虽未进行300 - 500人的安慰剂对照临床试验，但有两项临床试验表明其可减少自杀倾向和静坐不能，这是关键的中间终点，公司打算寻求加速批准，FDA将授予五年的营销权，期间可获得永久批准数据；对于NRX - 100，有随机对照数据表明其可减少自杀倾向和抑郁，预计NRX - 101和NRX - 100在2025年都有PDUFA日期[58][59][60][63][65] 问题：是否能找到有动力建立综合精神病中心的人，能否以建立全国性业务的方式收购他们[66] - 回答：经过广泛调查，已确定一些以正确方式运营的诊所，这些诊所将多种疗法结合在一个综合模型中，运营利润率约为30%，且部分已签署意向书，公司的商业模式是可行的，虽然这样的诊所目前是少数，但这种综合精准精神病学模型是必要的[67][68][69] 问题：在加入公司做尽职调查时，如何看待未来一年的收入构建[70] - 回答：从很多方面看这是一个数字游戏，有一定数量符合模型的诊所，可预期一定的盈利水平，通过已有的意向书和潜在收购的审计可构建模型；同时考虑NRX - 100和NRX - 101，从整体市场机会看，需求是存在的，如果公司能证明其解决方案能为患者提供更好的结果，就可以执行并实现收入构建[73][74][75][76] 问题：在合理估值下找到足够的精准精神病学诊所是否存在问题，估值是否波动很大，是否考虑过自建而非收购[79] - 回答：目前符合公司模型的诊所数量不足以建立全国性网络，公司将根据情况选择收购并增强其服务，或者自建诊所，不会接管那种业务混杂的医疗水疗中心[80][81] 问题：关于收入确认，是从签署之日起确认收入，还是会包括本季度初的历史数据[84] - 回答：这是一个复杂的问题，目前公司正在与审计师进行一系列对话以确定收入确认的基本规则，目前无法提供更多细节，未来公开讨论时将包含所有已知事实[85][86][87][88] 问题：在提供收入洞察或指导时，是否会提供这些实体业务水平的详细信息[89] - 回答：当公开讨论时，描述和披露将是完整的，涵盖当时所有已知事实，但目前还未到那一步[89]